NCT06051695 - A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | Biotech Hunter

Enrollment

230

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions

Solid Tumor, AdultColorectal CancerNSCLCNon Small Cell Lung CancerNSCLC, RecurrentNon-Small Cell Squamous Lung CancerPancreas CancerPancreatic NeoplasmColorectal AdenocarcinomaCRCColon CancerRectal CancerCancerOvarian CancerOvarian NeoplasmsMesotheliomaMesothelioma, MalignantOvary CancerLung CancerMESOM

Interventions

BIOLOGICAL

A2B694

Autologous logic-gated Tmod CAR T cells

DIAGNOSTIC_TEST

xT CDx with HLA-LOH Assay

An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device

Trial Locations (11)

10016

RECRUITING

NYU Langone Medical Center, New York

32224

RECRUITING

Mayo Clinic, Jacksonville

33606

RECRUITING

Moffitt Cancer Center, Tampa

55905

RECRUITING

Mayo Clinic Rochester, Rochester

63110

RECRUITING

Washington University, St Louis

85234

RECRUITING

Banner Health, Gilbert

90404

RECRUITING

UCLA Medical Center, Los Angeles

92093

RECRUITING

UCSD Moores Cancer Center, La Jolla

94305

RECRUITING

Stanford University, Stanford

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02114

RECRUITING

Massachusetts General Hopsital/Dana Farber Cancer Center, Boston